Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Nicholas S Wilson"'
Autor:
Randi B Gombos, Ana Gonzalez, Mariana Manrique, Dhan Chand, David Savitsky, Benjamin Morin, Ekaterina Breous-Nystrom, Christopher Dupont, Rebecca A Ward, Cornelia Mundt, Benjamin Duckless, Hao Tang, Mark A Findeis, Andrea Schuster, Jeremy D Waight, Dennis Underwood, Christopher Clarke, Gerd Ritter, Taha Merghoub, David Schaer, Jedd D Wolchok, Marc van Dijk, Jennifer S Buell, Jean-Marie Cuillerot, Robert Stein, Elise E Drouin, Nicholas S Wilson
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0191926 (2018)
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety o
Externí odkaz:
https://doaj.org/article/a2c5e638342c4ecea28b08aa00701413
Publikováno v:
Pattern Recognition. 124:108444
This paper presents a new approach to a robust Gaussian process regression, creating a non-parametric Bayesian regression estimate robust to outliers. Most existing approaches replace an outlier-prone Gaussian likelihood with a non-Gaussian likelihoo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f558bf1d4e7d3e64ebbab502325076e
https://doi.org/10.1016/j.patcog.2021.108444
https://doi.org/10.1016/j.patcog.2021.108444
Autor:
Marilyn Marques, Nicholas S. Wilson, Sylvia Dietrich, Jennifer Buell, Jeremy D. Waight, Rebecca Ward, Elena Paltrinieri, Dhan Chand, David Savitsky, Mark Bushell, Priyadarshini Iyer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an important negative regulator of the immune response to cancer that contributes to resistance/relapse to anti-PD-1 therapy.1 In clinical trials, anti-human (h) TIGIT antibodies ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78ed6a014c721944496dfb8f0dedb27b
https://doaj.org/article/0c75f32cdc34406ab96aba587ec1348b
https://doaj.org/article/0c75f32cdc34406ab96aba587ec1348b
Autor:
Nicholas S. Wilson, Dhan Chand, Min Lim, Dennis J. Underwood, Anthony W. Tolcher, Irina M. Shapiro, Anna Wijatyk, Mark Findeis, David Savitsky, Richard D. Carvajal, Jennifer Buell, Vignesh Venkatraman, Lernik Ohanjanian, James Strauss, Marc Van Dijk, Marilyn Marques, Claire Galand, Olga Ignatovich, Benjamin Morin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background CD137 (4-1BB) represents a costimulatory pathway that promotes T, NK, and dendritic cell effector functions favorable for antitumor immunity. The extracellular domain of CD137, comprised of four cysteine-rich domains (CRD-I, CRD-II, CRD-II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f712c7b381cf886a4f8a086b09560c22
https://doi.org/10.1136/jitc-2020-sitc2020.0377
https://doi.org/10.1136/jitc-2020-sitc2020.0377
Publikováno v:
Human Antibodies. 25:87-109
Co-stimulatory tumor necrosis factor receptors (TNFRs) can sculpt the responsiveness of T cells recognizing tumor-associated antigens. For this reason, agonist antibodies targeting CD137, CD357, CD134 and CD27 have received considerable attention for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a427983aeda3c188b8311866bd24840
https://doi.org/10.3233/hab-160308
https://doi.org/10.3233/hab-160308
Autor:
Randi Gombos, David Savitsky, Mark Bushell, Mathew Costa, Nicholas S. Wilson, R.B. Stein, Sylvia Dietrich, Jennifer Buell, Jeremy D. Waight, Elena Paltrinieri, Alexander Duncan, Dhan Chand
Publikováno v:
Cancer Research. 79:2390-2390
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) has emerged as an important regulator of the cancer-immunity cycle. Preclinical studies have demonstrated that TIGIT antibodies can enhance T and NK cell anti-tumor immunity, and therapeutic anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99ad2a040b4de8d8f369e4460b90e259
https://doi.org/10.1158/1538-7445.am2019-2390
https://doi.org/10.1158/1538-7445.am2019-2390
Autor:
Dhan Chand, Benjamin Morin, Jennifer Buell, Ekaterina Breous-Nystrom, Jeremy D. Waight, Jedd D. Wolchok, Taha Merghoub, Elise Drouin, Nicholas S. Wilson, Christopher Clarke, Marc Van Dijk, Christopher D. Dupont, Cornelia Anne Mundt, David Savitsky, Andrea Schuster, Mark Findeis, Dennis J. Underwood, Benjamin Duckless, Mariana Manrique, Rebecca Ward, Gerd Ritter, Randi Gombos, Ana M. Martín González, Robert Stein, Jean Marie Cuillerot, Hao Tang, David Schaer
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0191926 (2018)
PLoS ONE
PLoS ONE
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3531cae0cd1ba02aea8a8ea663edeca
http://europepmc.org/articles/PMC5884502?pdf=render
http://europepmc.org/articles/PMC5884502?pdf=render
Autor:
Kin-Ming Lo, Nicholas S. Wilson, Kenneth W. Hance, Robert Tighe, Helen Sabzevari, Robert Hofmeister, Yan Lan, Dong Zhang, Jeremy D. Waight, Shinji Takai, Guozhong Qin, Bo Marelli
Publikováno v:
The Journal of Immunology. 194:878-882
CD4+ regulatory T cells (Tregs) are critical for maintaining self-tolerance and function to prevent autoimmune disease. High densities of intratumoral Tregs are generally associated with poor patient prognosis, a correlation attributed to their broad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d376ed07ac6ae08a3f7e96e58ae7a7fa
https://doi.org/10.4049/jimmunol.1402725
https://doi.org/10.4049/jimmunol.1402725
Autor:
Antoine Tanne, Randi Gombos, Lukasz Swiech, Nicholas S. Wilson, Ana M. Martín González, Robert Stein, David Savitsky, Alex Duncan, Sylvia Dietrich, Jennifer Buell, Mariana Manrique, Jeremy D. Waight, Christopher D. Dupont, Ben A. Croker, Thomas Horn, Dhan Chand
Publikováno v:
Cancer Research. 78:2721-2721
Therapeutic antibodies targeting T cell co-inhibitory pathways, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1), have emerged as an important class of cancer therapies. Insights into how differe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::744a019b3b0df247b8d8635a367fbcba
https://doi.org/10.1158/1538-7445.am2018-2721
https://doi.org/10.1158/1538-7445.am2018-2721
Autor:
Joseph Connolly, Robert Stein, Reid Huber, Nicholas S. Wilson, Ekaterina Breous-Nystrom, Mark Findeis, Priyadarshini Iyer, Marc van Dijk, Peggy Scherle, Dennis J. Underwood, Christina Riordan, Horacio Nastri, Gregory Hollis, Michele Sanicola-Nadel, Jeremy D. Waight
Publikováno v:
Cancer Research. 78:3825-3825
Unprecedented rates of durable clinical responses have been observed for antibody-based therapeutics targeting immune checkpoint proteins such as cytotoxic T lymphocyte antigen-4 (CTLA-4) or programmed death receptor-1 (PD-1). Nonetheless, a signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::766eec68416fd0db980bd6a9f209b143
https://doi.org/10.1158/1538-7445.am2018-3825
https://doi.org/10.1158/1538-7445.am2018-3825